Gigaxonin fusion protein and methods for treating giant axonal neuropathy
The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells.
1. A fusion protein comprising gigaxonin coupled to at least one cell penetrant peptide selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; an arginine oligomer; a 41 kDa Cre recombinase peptide; and combinations thereof.
2. The fusion protein of claim 1 further comprising a linker sequence.
3. The fusion protein of claim 1 being a recombinant protein.
4. The fusion protein of claim 1 being chemically synthesized.
5. The fusion protein of claim 1 further comprising a pharmaceutically acceptable carrier.